158 related articles for article (PubMed ID: 32951952)
1. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma.
Jin H; Chalkidou A; Hawkins M; Summers J; Eddy S; Peacock JL; Coker B; Kartha MR; Good J; Pennington M;
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e143-e154. PubMed ID: 32951952
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care.
Raymakers AJN; Cameron D; Tyldesley S; Regier DA
Curr Oncol; 2021 May; 28(3):1857-1866. PubMed ID: 34068400
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases.
Kim H; Gill B; Beriwal S; Huq MS; Roberts MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1175-83. PubMed ID: 27130789
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer.
Kumar A; Straka C; Courtney PT; Vitzthum L; Riviere P; Murphy JD
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1185-1194. PubMed ID: 33002541
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial.
Lourenco RA; Khoo T; Crothers A; Haas M; Montgomery R; Ball D; Bressel M; Siva S
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):968-976. PubMed ID: 36395809
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer.
Mutsaers A; Greenspoon J; Walker-Dilks C; Swaminath A
Radiat Oncol; 2017 Jun; 12(1):110. PubMed ID: 28662680
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare.
Parikh ND; Marshall VD; Green M; Lawrence TS; Razumilava N; Owen D; Singal AG; Feng M
J Med Imaging Radiat Oncol; 2018 Oct; 62(5):673-681. PubMed ID: 29877615
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
Leung HW; Liu CF; Chan AL
Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.
Cucchetti A; Piscaglia F; Cescon M; Colecchia A; Ercolani G; Bolondi L; Pinna AD
J Hepatol; 2013 Aug; 59(2):300-7. PubMed ID: 23603669
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma.
Takeda A; Sanuki N; Eriguchi T; Kobayashi T; Iwabutchi S; Matsunaga K; Mizuno T; Yashiro K; Nisimura S; Kunieda E
J Gastroenterol Hepatol; 2014 Feb; 29(2):372-9. PubMed ID: 23927053
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma.
Su TS; Liang P; Liang J; Lu HZ; Jiang HY; Cheng T; Huang Y; Tang Y; Deng X
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):639-646. PubMed ID: 28581406
[TBL] [Abstract][Full Text] [Related]
13. Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring.
Lee YYD; Nguyen DT; Moodie T; O'Brien R; McMaster A; Hickey A; Pritchard N; Poulsen P; Tabaksblat EM; Weber B; Worm E; Pryor D; Chu J; Hardcastle N; Booth J; Gebski V; Wang T; Keall P
BMC Cancer; 2021 May; 21(1):494. PubMed ID: 33941111
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma.
Guarneri A; Franco P; Romagnoli R; Trino E; Mirabella S; Molinaro L; Rizza G; Filippi AR; Carucci P; Salizzoni M; Ricardi U
Radiol Med; 2016 Nov; 121(11):873-881. PubMed ID: 27447803
[TBL] [Abstract][Full Text] [Related]
15. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile?
Rim CH; Lee HY; Kim JS; Kim H
Int J Radiat Biol; 2021; 97(2):111-119. PubMed ID: 33253598
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases.
Verma V; Yegya-Raman N; Sprave T; Han G; Kantarjian HM; Welsh JW; Chang JY; Lin SH
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):977-988. PubMed ID: 35675852
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.
Kim N; Kim HJ; Won JY; Kim DY; Han KH; Jung I; Seong J
Radiother Oncol; 2019 Feb; 131():81-87. PubMed ID: 30773192
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC).
Donovan EK; Xie F; Louie AV; Chu W; Siva S; Kapoor A; Swaminath A
Clin Genitourin Cancer; 2022 Oct; 20(5):e353-e361. PubMed ID: 35490099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]